Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00370747 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT00370747: Completed Phase 2 study, sponsored by Bausch & Lomb Incorporated.
NCT00370747 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 162 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00370747, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome
Primary Outcome
ocular signs, including corneal and conjunctival staining, tear film breakup time and blink rate, and ocular symptoms, including burning or stinging, itchiness or scratchiness, grittiness or sandiness, foreign body sensation, haziness or blurriness, photophobia, photopsia, and eye discomfort
Interventions
- DRUG Placebo
- DRUG Ecabet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00370747 record still lists
NCT00370747 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00370747 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00370747 about?
NCT00370747 is a clinical study titled "Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome". The purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome
What is the current status of trial NCT00370747?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2006-09. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00370747?
The interventions under investigation include: Placebo (DRUG), Ecabet (DRUG).
Who is sponsoring clinical trial NCT00370747?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00370747's enrollment target sits among peer trials
162 418th of 2000 higher than 1,579 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia